U.S. Patent Application No. 09/023,401 Amendment F March 25, 2005

Claim Listing

Claims 1-40 (canceled)

- 41. (previously presented) The pharmaceutical composition of claim 70, wherein R is a straight chain alkyl having a chain length of C₇ to C₁₂, and W, X, Y, and Z are each hydrogen.
 - 42. (original) The pharmaceutical composition of claim 41, wherein R is nonyl.

Claims 43-51 (canceled)

52. (previously presented) The pharmaceutical composition of claim 70, wherein R is nonyl and W, X, Y, and Z are each butanoyl.

Claims 53-55 (canceled)

- 56. (currently amended) The pharmaceutical composition of claim 70, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is selected from the group consisting of N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol, tetrabutyrate, and said antiviral compound is (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate [[(3TC)]].
- 57. (original) The pharmaceutical composition of claim 56, wherein said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound [[in]] is N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol.
- 58. (previously presented) The pharmaceutical composition of claim 70, wherein said first amount of said N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound is in the range of from about 0.1 mg to about 100 mg.

Claims 59-60 (canceled)

U.S. Patent Application No. 09/023,401 Amendment F March 25, 2005

61. (previously presented) The pharmaceutical composition of claim 70, wherein said second amount of said antiviral compound, or mixture thereof, is in the range of from about 0.1 mg to about 500 mg.

Claims 62-68 (canceled)

- 69. (original) A pharmaceutical composition for treating a hepatitis B virus infection in a human patient, comprising from about 0.1 mg to about 100 mg of N-(n-nonyl)-1,5-dideoxy-1,5-imino-D-glucitol and from about 0.1 mg to about 500 mg of (-)-2'-deoxy-3'-thiocytidine-5' triphosphate.
- 70. (currently amended) A pharmaceutical composition for treating hepatitis virus infection, comprising a first amount of an N-substituted-1,5-dideoxy-1,5-imino-D-glucitol compound of Formula I:

wherein:

R is selected from the group consisting of straight chain alkyl having a chain length of C₇ to C₁₂, and

W, X, Y, and Z are each independently selected from the group consisting of hydrogen, and butanoyl; and

a second amount of an antiviral compound selected from the group consisting of 2',3'-dideoxycytidine, [[(ddC).]] 2',3'-dideoxycytidine-5'-triphosphate, (-)-2',3'-dideoxy-3'-thiacytidine, (-)-2'-deoxy-3'-thiocytidine-5'-triphosphate, [[(3TC).]] and mixtures thereof, and

U.S. Patent Application No. 09/023,401 Amendment F March 25, 2005

a pharmaceutically acceptable carrier, diluent, or excipient

wherein said first and second amounts of said compounds together comprise an anti-hepatitis virus effective amount of said compounds.

Claims 71-75 (canceled)